These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 2693115

  • 1. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
    Bard JM, Luc G, Douste-Blazy P, Drouin P, Ziegler O, Jacotot B, Dachet C, De Gennes JL, Fruchart JC.
    Eur J Clin Pharmacol; 1989; 37(6):545-50. PubMed ID: 2693115
    [Abstract] [Full Text] [Related]

  • 2. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
    [Abstract] [Full Text] [Related]

  • 3. [Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia].
    Caruzzo C, Uslenghi E, Varbella F, Caruzzo E, Marcolongo M, Brusca A.
    Minerva Cardioangiol; 1989 Dec; 37(12):509-15. PubMed ID: 2695857
    [Abstract] [Full Text] [Related]

  • 4. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia].
    Riesen WF, Keller U, Del Bufalo A, Reutter FW, Baur HR, Golay A, Bertel O, Kummer H, Kistler H, Ammann F.
    Schweiz Med Wochenschr; 1989 Dec 02; 119(48):1719-23. PubMed ID: 2694363
    [Abstract] [Full Text] [Related]

  • 5. Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Stohler R, Keller U, Riesen WF.
    Eur J Clin Pharmacol; 1989 Dec 02; 37(2):199-203. PubMed ID: 2507323
    [Abstract] [Full Text] [Related]

  • 6. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
    Bard JM, Parra HJ, Camare R, Luc G, Ziegler O, Dachet C, Bruckert E, Douste-Blazy P, Drouin P, Jacotot B.
    Metabolism; 1992 May 02; 41(5):498-503. PubMed ID: 1588829
    [Abstract] [Full Text] [Related]

  • 7. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P, Bojanovski M, Jochim A, Canzler H, Bojanovski D.
    Lancet; 1988 Mar 19; 1(8586):611-3. PubMed ID: 2894548
    [Abstract] [Full Text] [Related]

  • 8. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.
    Ide H, Fujiya S, Aanuma Y, Agishi Y.
    Clin Ther; 1990 Mar 19; 12(5):410-20. PubMed ID: 2268863
    [Abstract] [Full Text] [Related]

  • 9. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
    Thiery J, Creutzfeldt C, Creutzfeldt W, Walli AK, Seidel D.
    Klin Wochenschr; 1990 Aug 17; 68(16):814-22. PubMed ID: 2214604
    [Abstract] [Full Text] [Related]

  • 10. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
    Mol MJ, Stuyt PM, Demacker PN, Stalenhoef AF.
    Neth J Med; 1990 Apr 17; 36(3-4):182-90. PubMed ID: 2355995
    [Abstract] [Full Text] [Related]

  • 11. Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
    Agheli N, Jacotot B.
    Br J Clin Pharmacol; 1991 Oct 17; 32(4):423-8. PubMed ID: 1958434
    [Abstract] [Full Text] [Related]

  • 12. HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
    Castelao AM, Griñó JM, Andrés E, Gilvernet S, Serón D, Castiñeiras MJ, Roca M, Galcerán JM, González MT, Alsina J.
    Transplant Proc; 1993 Feb 17; 25(1 Pt 2):1043-6. PubMed ID: 8442035
    [No Abstract] [Full Text] [Related]

  • 13. Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
    Matthys E, Schurgers M, Lamberigts G, Lameire N, Vandecasteele N, Labeur C, Beisiegel U, Rosseneu M.
    Atherosclerosis; 1991 Feb 17; 86(2-3):183-92. PubMed ID: 1872912
    [Abstract] [Full Text] [Related]

  • 14. Effects of simvastatin on the number and composition of apoproteinB-containing lipoproteins in hypercholesterolemia: analysis of apoproteinB in each lipoprotein fraction by highly sensitive latex method.
    Ikeda Ryomoto K, Suzuki M, Tsushima M, Yamamoto A, Harano Y.
    Endocr J; 1996 Oct 17; 43(5):469-75. PubMed ID: 8980885
    [Abstract] [Full Text] [Related]

  • 15. Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.
    Mölgaard J, von Schenck H, Olsson AG.
    Eur Heart J; 1988 May 17; 9(5):541-51. PubMed ID: 3402470
    [Abstract] [Full Text] [Related]

  • 16. Effect of simvastatin treatment on plasma apolipoproteins and hepatic apolipoprotein mRNA levels in the genetically hypercholesterolemic rat (RICO).
    Felgines C, Sérougne C, Mathé D, Mazur A, Lutton C.
    Life Sci; 1994 May 17; 54(5):361-7. PubMed ID: 8289597
    [Abstract] [Full Text] [Related]

  • 17. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Jacob BG, Möhrle W, Richter WO, Schwandt P.
    Eur J Clin Pharmacol; 1992 May 17; 42(4):353-8. PubMed ID: 1516599
    [Abstract] [Full Text] [Related]

  • 18. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P, Heinonen T, Shurzinske L, Black DM.
    Atherosclerosis; 1997 Aug 17; 133(1):123-33. PubMed ID: 9258416
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
    Feillet C, Farnier M, Monnier LH, Percheron C, Colette C, Descomps B, Crastes De Paulet A.
    Atherosclerosis; 1995 Dec 17; 118(2):251-8. PubMed ID: 8770319
    [Abstract] [Full Text] [Related]

  • 20. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, Thompson GR.
    Atherosclerosis; 1996 Jan 26; 119(2):203-13. PubMed ID: 8808497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.